Compare PAGSEG Inc (PAGS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs State Street SPDR S&P Biotech ETF — how do they compare? PAGSEG Inc trades at $9.6 (market cap $2.69B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: PAGSEG Inc pays a 11.49% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, PAGSEG Inc nearer its low. Which is the better fit depends on your goals.
| PAGS | XBI | |
|---|---|---|
Market Cap | $2.69B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $12.00 | $169.55 |
52-Week Low | $8.44 | $93.43 |
Enterprise Value | $10.60B | — |
Dividend Yield | 11.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $9.75, up 0.21% today, with a bullish technical signal from moving averages and a consensus analyst price target of $11.45. The company reported Q2 2026 EPS of $0.41, beating expectations, and maintains solid fundamentals with a P/E of 6.67 and net income margin of 10.45%. Recent news highlights institutional investments and management continuity despite leadership changes.
The outlook is positive with attractive valuation and growth potential, but risks include macroeconomic challenges in Brazil and competitive pressures. Upside is supported by analyst buy ratings and dividend payments, though investors should monitor credit loss trends and interest rate impacts on profitability.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
